Lymphoproliferative Disorders D008232

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders

Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders

Description

Disorders characterized by proliferation of lymphoid tissue, general or unspecified.   MeSH

Subtype Terms (21)

Agammaglobulinemia
24 drugs (22 approved, 2 experimental)

Autoimmune Lymphoproliferative Syndrome
5 approved drugs

Castleman Disease
22 drugs (20 approved, 2 experimental)

Granuloma
38 drugs (29 approved, 9 experimental)

Heavy Chain Disease
 

Immunoblastic Lymphadenopathy
1 approved drug

Immunoglobulin Light-chain Amyloidosis
54 drugs (40 approved, 14 experimental)

Immunoproliferative Small Intestinal Disease
 

Infectious Mononucleosis
7 drugs (4 approved, 3 experimental)

Leukemia, Hairy Cell
88 drugs (61 approved, 27 experimental)

Leukemia, Lymphoid
134 drugs (80 approved, 54 experimental)

Lymphangiomyoma
1 approved drug

Lymphoma
958 drugs (376 approved, 582 experimental)

Macrophage Activation Syndrome
8 drugs (7 approved, 1 experimental)

Marek Disease
 

Multiple Myeloma
859 drugs (294 approved, 565 experimental)

Plasmacytoma
86 drugs (59 approved, 27 experimental)

Sarcoidosis
53 drugs (41 approved, 12 experimental)

Sezary Syndrome
122 drugs (80 approved, 42 experimental)

Tumor Lysis Syndrome
4 approved drugs

Waldenstrom Macroglobulinemia
171 drugs (93 approved, 78 experimental)



Organization Involved with Phase 4 Indications (3)

Organization Involved with Other Experimental Indications (4)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.